Funding profile · Consumer health AI
Galen AI
A Y Combinator company that raised a small, mostly undisclosed amount of outside capital before Oura Health acquired it about eleven months later. No SEC Form D was ever filed under the company’s name, and neither side disclosed what Oura paid.
Data as of September 25, 2026. Company-reported figures are labeled.
Rounds at a glance
| When | Round | Amount | Investors | Source |
|---|---|---|---|---|
| Apr 2025 | Accelerator, Y Combinator Spring 2025 (X25) | $500,000 | Y Combinator | Data aggregator |
| Jun 2025 | Early stage VC | Not disclosed | Niremia Collective | Data aggregator |
| Apr 17, 2026 | Acquisition (M&A), completed | Not disclosed | Oura Health (acquirer) | Company release |
What the filings show
No Form D appears under “Galen AI,” “Galen,” or any close variant in an SEC EDGAR company search for Regulation D notices as of September 25, 2026. That means either the $500,000 accelerator round and the June 2025 early stage round were raised under an exemption that does not require a Form D, such as Section 4(a)(2), or the rounds fell under a reporting threshold, or a Form D was filed under an entity name not captured by this search. A small round from one accelerator and one named venture fund is the kind of financing that sometimes moves without a Regulation D notice.
Oura Health, the acquirer, is itself a private company. It has not filed with the SEC, so there is no filing on the buyer’s side to check the acquisition price against either.
Reading the record
- No Form D exists for this company.An EDGAR company search for “Galen” under Form D returns dozens of unrelated entities, mostly investment funds and one apartment complex, but nothing named Galen AI. The absence does not mean no money moved, since Regulation D exemptions have reporting gaps, but it does mean the standard public-record check available for most venture-backed companies is not available here.
- The accelerator round matches YC’s standard deal.PitchBook records a $500,000 accelerator investment dated April 1, 2025, which lines up with the company’s participation in Y Combinator’s Spring 2025 batch and with YC’s publicly known standard terms for that period.
- One named investor for the next round.PitchBook records an early stage VC round dated June 1, 2025 with Niremia Collective as the investor of record. Niremia is a real, active fund; TechCrunch reported in February 2024 that it had closed a $22.5 million inaugural fund focused on well-being technology, a thesis that fits a consumer health app like Galen. Neither the amount raised nor a lead versus participating role is disclosed.
- Announced versus filed does not apply here, because nothing was filed.Unlike companies with a Form D on record, there is no filed number to compare against an announced number. Both the accelerator round and the early stage round are known only through a single data aggregator, PitchBook, which itself shows no dollar figure for the June 2025 round.
- The acquisition price is withheld on both sides.Oura’s own release does not mention a number. HLTH’s coverage states plainly that “financial terms were not disclosed.” No other outlet found one either.
- Headcount is a rough proxy for deal size.PitchBook lists 2 employees at the time of its data capture, consistent with a two-founder team rather than a large organization, though it does not by itself say anything about what Oura paid for the technology and the team.
Commercial signals
| Signal | Detail | Source type |
|---|---|---|
| Regulatory | No FDA clearance or PMA found. Consistent with a consumer wellness app, not a regulated device. | Not found |
| Data integration scope | 800-plus healthcare institutions, 12,000-plus locations across the US, UK, and Canada, and 20-plus wearables, per the company; repeated by press without independent verification. | Company-stated |
| User traction | Described as a consumer app in beta testing through most of its independent life, reachable by waitlist and private beta. No user counts disclosed. | Not found |
| Acquisition | Completed Apr 17, 2026. Oura acquired the technology and brought the team on board. | Public record |
| Acquirer’s pattern | Oura’s third health-tech acquisition in roughly two years, after Veri and Sparta Science in 2024 and Doublepoint in March 2026, alongside a $908M Series E in October 2025 at an $11B valuation. | Independent |
What to watch
- Whether an amended or late Form D ever surfaces for either the accelerator round or the June 2025 round.
- Whether Oura or Galen’s founders ever disclose the acquisition price, in a later filing, interview, or Oura fundraising document.
- Whether Niremia Collective discloses the size of its Galen AI investment in its own reporting.
- Whether Galen’s data-integration technology shows up as a named feature inside Oura Advisor, which would be the clearest sign of how the deal is being used.
The Galen AI story on Healthcare DiscoveryHealthcare Discovery
Related companies
Sources
- IndependentGalen AI company profile: valuation, investors, acquisition
- Public recordSEC EDGAR company search for “Galen,” Form D filings; no entity named Galen AI found
- IndependentNiremia Collective closes inaugural fund with $22.5M focused on well-being technology
- IndependentNiremia Collective investments page
- CompanyOURA Welcomes Galen AI Team, Acquires Technology to Advance Connected Health AI Roadmap
- IndependentOURA Acquires Galen AI to Integrate Clinical Data with Biometric Insights
- IndependentOura Acquires AI-Powered Health Companion Galen AI
- IndependentOura Acquires Galen AI to Link Rings to Medical Records
- CompanyGalen AI company page
Compiled from SEC and other public records and published reports as of September 25, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date. Healthcare Venture Capital Fund holds no position in Galen AI. This page is not an offer to sell or a recommendation to buy any security.